Edition:
United Kingdom

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

0.52USD
18 Apr 2019
Change (% chg)

$-0.01 (-1.71%)
Prev Close
$0.53
Open
$0.52
Day's High
$0.54
Day's Low
$0.52
Volume
2,353,759
Avg. Vol
2,884,507
52-wk High
$2.58
52-wk Low
$0.49

Latest Key Developments (Source: Significant Developments)

Novavax Reports Q4 Loss Per Share $0.13
Monday, 18 Mar 2019 

March 18 (Reuters) - Novavax Inc ::NOVAVAX REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.13.Q4 REVENUE $6.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $7.1 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.NOVAVAX - AS OF DEC 31, 2018, HAD $103.9 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH, VERSUS $186.4 MILLION AS OF DEC 31, 2017.  Full Article

Novavax Q3 Revenue $7.7 Mln Vs I/B/E/S View $9.4 Mln
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Novavax Inc ::NOVAVAX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.12.Q3 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $7.7 MILLION VERSUS I/B/E/S VIEW $9.4 MILLION.ON TRACK TO MEET 2018 OBJECTIVES.AS OF SEPT 30, CO HAD $145.6 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH.  Full Article

Novavax Says Co And Cadila Pharmaceuticals Entered Agreement To Permit CPLB To Develop Some Cadila Biological Products
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Novavax Inc ::NOVAVAX - ON JULY 18, CO AND CADILA PHARMACEUTICALS ENTERED INTO SECOND AMENDED, RESTATED JOINT VENTURE AGREEMENT FOR CPL BIOLOGICALS PRIVATE LIMITED.NOVAVAX - PURSUANT TO AGREEMENT, CO, CADILA AMENDED AND RESTATED CERTAIN TERMS RELATED TO FIRST AMENDED AND RESTATED JOINT VENTURE AGREEMENT FOR CPLB.NOVAVAX - AGREEMENTS PERMIT CPLB TO DEVELOP SOME CADILA BIOLOGICAL PRODUCTS & TO DEVELOP CERTAIN PRODUCTS USING CO'S NANOPARTICLE VACCINE PRODUCTION.NOVAVAX-AGREEMENTS PERMIT CPLB TO DEVELOP SOME CADILA BIOLOGICAL PRODUCTS USING CO'S ANTIGEN SPECIFIC SEED DEVELOPMENT, PROTEIN EXPRESSION, OTHERS.  Full Article

Novavax Inc Promotes John Trizzino To CFO Role
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Novavax Inc ::NOVAVAX PROMOTES JOHN J. TRIZZINO TO EXPANDED ROLE AS CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER.NOVAVAX - TRIZZINO HAS BEEN SERVING AS SVP, COMMERCIAL OPERATIONS, SINCE 2014.  Full Article

Novavax Inc Q4 Loss Per Share $0.16
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Novavax Inc ::NOVAVAX PROVIDES CORPORATE UPDATE AND REPORT OF FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.16.Q4 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.Q4 REVENUE $10.4 MILLION VERSUS $5.4 MILLION.Q4 REVENUE VIEW $8 MILLION -- THOMSON REUTERS I/B/E/S.JOHN J. TRIZZINO APPOINTED CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER.  Full Article

Novavax CEO Stanley Erck reports open market purchase of 100,000 co's common shares
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Novavax Inc :Novavax Inc says CEO Stanley Erck reports open market purchase of 100,000 co's common shares at average price of $1.13per share on november 9 - sec filing.  Full Article

Novavax reports Q3 loss per share $0.15
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Novavax Inc ::Novavax reports third quarter 2017 financial results.Q3 loss per share $0.15.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 revenue $8.4 million versus $3.2 million.Q3 revenue view $6.4 million -- Thomson Reuters I/B/E/S.  Full Article

Novavax Q3 loss per share $0.15
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Novavax Inc ::Novavax reports third quarter 2017 financial results.Q3 loss per share $0.15.Q3 revenue $8.4 million versus $3.2 million.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 revenue view $6.4 million -- Thomson Reuters I/B/E/S.Novavax - ‍as of Sept 30, 2017, co had $172.6 million in cash, cash equivalents and marketable securities, compared to $235.5 million as of Dec 31, 2016​.  Full Article

Novavax announces leadership change
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Novavax Inc ::Novavax announces leadership change.Novavax Inc - ‍Barclay Phillips has submitted his resignation as senior vice president, chief financial officer (CFO) and treasurer​.Novavax Inc - ‍Erck will act as interim CFO pending completion of a search for a new chief financial officer​.  Full Article

Novavax initiates phase 1/2 trial of Nanoflu vaccine in older adults
Tuesday, 19 Sep 2017 

Sept 19 (Reuters) - Novavax Inc :Novavax initiates phase 1/2 trial of Nanoflu vaccine in older adults.Novavax Inc - ‍data from phase 1/2 trial of Nanoflu expected by end of 2017.  Full Article

UPDATE 1-Novavax respiratory infection vaccine fails in late-stage trial

Feb 28 Novavax Inc said on Thursday its vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late stage study.